Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of encorafenib and cetuximab with or without binimetinib versus irinotecan/cetuximab or FOLFIRI/cetuximab in BRAF V600E-mutant metastatic colorectal cancer
MOH_2017-03-15_000199Phase 3Not yet recruiting
- Sponsor
- Array BioPharma
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib, cetuximab, binimetinib, irinotecan, fluorouracil and 1 more in colorectal cancer (CRC) (3 arms), sponsored by Array BioPharma. Primary endpoint: Overall survival. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
encorafenibcetuximabbinimetinibirinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2017-03-15_000199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-15_000199.